Compare Crispr Therapeutics AG (CRSP) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Plug Power Inc — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Plug Power Inc trades at $2.3 (market cap $3.17B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Plug Power Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PLUG | |
|---|---|---|
Market Cap | $4.97B | $3.17B |
Sector | Health | Industrials |
52-Week High | $76.78 | $4.14 |
52-Week Low | $44.34 | $1.40 |
Enterprise Value | $3.32B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Plug Power (PLUG) trades at $2.17, down 2.69% with a bearish technical signal. The company shows persistent financial challenges with negative profit margins (-227.13% net income margin) and cash flow issues, though recent asset sales aim to improve liquidity. Revenue grew to $710M in 2025 but remains unprofitable with significant losses. Analyst sentiment is mixed with 44.7% buy ratings and a $2.92 consensus target, while technical indicators show oversold conditions with RSI at 18.61.
The outlook remains challenging with profitability projected for 2028, but execution risks and continued cash burn pose significant hurdles. Near-term catalysts include $80M liquidity from recent asset sales and project milestones, though elevated short interest at 27.4% reflects skepticism. Investors face high volatility amid the company's turnaround efforts in the competitive hydrogen sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
